Celgene Further Commits To Neuroscience With Prothena Pact

It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars...

      

Related Stories

• TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
• Merger Buzz Boosts Shares Of India's Troubled Fortis
• Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

 

Original Article: Celgene Further Commits To Neuroscience With Prothena Pact

More From BioPortfolio on "Celgene Further Commits To Neuroscience With Prothena Pact"